Detail Information
Publications
BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumorsNatalie Minkovsky
University of Pennsylvania, School of Medicine, and Abramson Cancer Center, Department of Pathology and Laboratory Medicine, 252 John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104, USA
Curr Opin Investig Drugs 9:1336-46. 2008..BIBW-2992 was granted Fast-Track status by the FDA for NSCLC and was investigated in phase III trials for this indication...
